Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil

doi:10.5306/wjco.v12.i4.249

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 4

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5122)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-7) series.

Item

Count

PDF

216

WORD

252

HTML

2034

Figures (1-1)

356

Tables (1-7)

572

Sum=3430

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

472

Download

1220

Sum=1692

Apr 24, 2021 (publication date) through Feb 8, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Cohort Study

World J Clin Oncol. Apr 24, 2021; 12(4): 249-261
Published online Apr 24, 2021. doi: 10.5306/wjco.v12.i4.249

Table 6 Univariable and multivariable analyses of prognostic factors in esophageal cancer

	Relapse-free survival
	Univariate			Multivariate
	RR	95%CI	P value	RR	95%CI	P value
Age	0.982	0.935-1.033	0.468
Male/Female	2.211	0.638-5.920	0.1885
Location, MtLtAe/CeUt	1.230	0.406-3.090	0.689
Tumor grade, other/por	2.612	1.050-6.026	0.040	1.412	0.498-3.785	0.503
pT, 0▪1▪2/3▪4	4.554	1.983-10.770	0.0004	1.195	0.433-3.432	0.734
pN, 0/1▪2▪3	5.287	2.062-16.320	0.0003	3.172	1.074-10.710	0.036
pM, 0/1	2.543	0.726-6.977	0.131
pStage, 0▪1▪2/3▪4	8.655	3.652-22.060	< 0.0001	2.449	0.356-16.800	0.357
pCR (primary tumor), CR (+)/nonCR (-)	5.199	1.501-32.770	0.0063	1.878	0.337-15.060	0.487
CT-PET-T, (-)/(+)	2.561	1.059-7.120	0.0036
CT-PET-N, (-)/(+)	10.810	4.251-28.160	< 0.0001	22.570	4.694-177.800	< 0.0001
CT-PET-CMR, (-)/(+)	2.523	1.034-7.063	0.041

Ae: Abdominal esophagus; Ce: Cervical esophagus; CI: Confidence interval; CR: Complete response; CT-PET-N: Computed tomography-positron emission tomography negative N; CT-PET-T: Computed tomography-positron emission tomography negative T; Lt: Lower thoracic esophagus; Mt: Middle thoracic esophagus; pCR: Pathological complete response; PET-CMR: Positron emission tomography-complete metabolic response; por: Poorly differentiated carcinoma; RR: Relative risk; Ut: Upper thoracic esophagus.

Citation: Suzuki K, Etoh T, Shibata T, Nishiki K, Fumoto S, Ueda Y, Shiroshita H, Shiraishi N, Inomata M. Positron emission tomography complete metabolic response as a favorable prognostic predictor in esophageal cancer following neoadjuvant chemotherapy with docetaxel/cisplatin/5-fluorouracil. World J Clin Oncol 2021; 12(4): 249-261
URL: https://www.wjgnet.com/2218-4333/full/v12/i4/249.htm
DOI: https://dx.doi.org/10.5306/wjco.v12.i4.249